Drugs that contain Pilocarpine Hydrochloride
1. Qlosi patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11129812 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(13 years from now) | |
| US10639297 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(13 years from now) | |
| US9867810 | ORASIS PHARMS | Ophthalmic pharmaceutical compositions and uses relating thereto |
Aug, 2037
(13 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Oct 17, 2026 |
Market Authorisation Date: 17 October, 2023
Treatment: Treatment of presbyopia
Dosage: SOLUTION;OPHTHALMIC
More Information on Dosage
QLOSI family patents
2. Vuity patents expiration
VUITY's oppositions filed in EPO
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US10610518 | ABBVIE | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| US11285134 | ABBVIE | Presbyopia treatments |
Apr, 2039
(15 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Dosing Schedule(D-187) | Mar 28, 2026 |
| New Product(NP) | Oct 28, 2024 |
Market Authorisation Date: 28 October, 2021
Treatment: Use of vuity for the treatment of presbyopia in adults
Dosage: SOLUTION;OPHTHALMIC
How can I launch a generic of VUITY before it's drug patent expiration?
More Information on Dosage
VUITY family patents